Anzeige
Mehr »
Montag, 23.06.2025 - Börsentäglich über 12.000 News
Einmalige Gelegenheit?: Eines der aufregendsten Junior-Goldexplorationsprojekte in Australien im Fokus!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QB6B | ISIN: US26818M1080 | Ticker-Symbol:
NASDAQ
23.06.25 | 21:59
10,180 US-Dollar
-1,36 % -0,140
1-Jahres-Chart
DYNE THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
DYNE THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur DYNE THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiH.C. Wainwright reiterates buy rating on Dyne Therapeutics stock2
DiDyne falls amid delay in clinical program for muscle disorder therapy2
DiDyne Therapeutics stock falls after updated plan for accelerated approval in DM11
DiDyne Therapeutics Submits Revised ACHIEVE Trial Protocol To FDA Elevating VHOT To Primary Endpoint295WASHINGTON (dpa-AFX) - Dyne Therapeutics (DYN) announced the FDA has granted Breakthrough Therapy Designation to DYNE-101 for the treatment of myotonic dystrophy type 1. The company also announced...
► Artikel lesen
DiDyne Therapeutics, Inc.: Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-101 and Updated Plan for Accelerated Approval in DM1 Following Type C Meeting90- Based on Type C meeting and new data, Dyne submitted revised ACHIEVE trial protocol to FDA elevating vHOT to primary endpoint for U.S. Accelerated Approval - - New positive clinical data from Phase...
► Artikel lesen
DiDyne Therapeutics, Inc. - 8-K, Current Report3
05.06.Dyne Therapeutics, Inc. - 8-K, Current Report3
05.06.Dyne Therapeutics, Inc.: Dyne Therapeutics to Present New Preclinical Data in Facioscapulohumeral Muscular Dystrophy at the FSHD Society International Research Congress-
DYNE THERAPEUTICS Aktie jetzt für 0€ handeln
02.06.Oppenheimer assumes Dyne Therapeutics stock at outperform, PT $341
13.05.Stifel maintains Buy on Dyne stock with $66 target post-meeting1
08.05.Dyne Therapeutics, Inc. Q1 Loss Increases, Misses Estimates381WASHINGTON (dpa-AFX) - Dyne Therapeutics, Inc. (DYN) revealed Loss for its first quarter that increased from last year and missed the Street estimates.The company's earnings came in at -$115.361...
► Artikel lesen
08.05.Dyne Therapeutics, Inc.: Dyne Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights254- FDA (CDER) Type C meeting held in May 2025 for DYNE-101 in DM1 and Dyne plans to provide a regulatory update following receipt of meeting minutes - - Registrational Expansion Cohort of ACHIEVE...
► Artikel lesen
08.05.Dyne Therapeutics, Inc. - 8-K, Current Report6
08.05.Dyne Therapeutics, Inc. - 10-Q, Quarterly Report3
25.04.EC grants orphan drug designation to Dyne Therapeutics' DMD therapy2
24.04.Dyne Therapeutics-Aktie steigt nach Erhalt des Orphan-Drug-Status1
24.04.Dyne Therapeutics stock rises on orphan drug status1
24.04.EC grants orphan drug status to Dyne's DMD treatment3
24.04.Dyne Therapeutics, Inc.: Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-251 in Duchenne Muscular Dystrophy255- Recently presented data demonstrated sustained functional improvement with DYNE-251 treatment through 18 months - - Data from the fully enrolled DELIVER registrational expansion cohort is planned...
► Artikel lesen
15.04.Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Chief Business Officer and Chief Scientific Officer Appointments309- Vikram Ranade, PhD, appointed as chief business officer - - Ranjan Batra, PhD, appointed as chief scientific officer - - Oxana Beskrovnaya, PhD, transitioning to chief innovation officer - WALTHAM...
► Artikel lesen
Weiter >>
73 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1